Hear What Colin Hill had to say to Sidley on AI Use in Drug Discovery

Sydley 300x300 1

Stephen Abreu, Sidley partner, talks to our Colin Hill about how the use of AI is revolutionizing the biotech space. Colin explains how our ability to predict and understand the actions of biological systems has historically been limited because of the complexity of “genetic circuitry,” but AI has allowed us to develop a more quantitative […]

Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023

CTAD 2023 1

We are delighted to announce that Aitia will be at the Clinical Trials on Alzheimer’s Disease conference (CTAD) being held from October 24-27 in Boston, MA. We will be presenting a poster focused on prediction of Amyloid PET positivity of Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on blood-based biomarkers and […]

A Digital Boost for Pharmaceutical R&D: Join our CEO, Colin Hill at the Orion Day in Finland

Orion Day

We are thrilled to announce that Aitia will be participating at the Orion Day conference. Our CEO, Colin Hill, will be giving a keynote titled:  AI-Powered Digital Twins: Revolutionizing Pharmaceutical Drug Discovery and Clinical Development to Create the Next Generation of Breakthrough Drugs. During the keynote, Colin will share valuable insights and engage in a dynamic […]

Webinar | From the beta-amyloid hypothesis to AI-driven discoveries of novel biomarkers and breakthrough drugs in Alzheimer’s Disease

Webinar Video

Alzheimer’s disease research has taken center stage in the world of drug discovery and clinical development. The convergence of causal AI, supercomputing power, and multi-omic human data is allowing us to begin to unravel the molecular circuity of this debilitating disease in order to discover the next generation of breakthrough drugs and predictive biomarkers. In […]